TY - JOUR
T1 - Characterising the prevalence of overweight and obese status among adults with sickle cell disease
AU - Sickle Cell Disease Implementation Consortium
AU - Ibemere, Stephanie O.
AU - Oyedeji, Charity I.
AU - Preiss, Liliana
AU - Van Althuis, Laura E.
AU - Hankins, Jane S.
AU - Azul, Melissa
AU - Burns, Ebony N.
AU - Glassberg, Jeffrey
AU - Hagar, Ward
AU - Hussain, Faiz
AU - King, Allison
AU - Melvin, Cathy
AU - Myers, John
AU - Snyder, Angela
AU - Shah, Nirmish
AU - Tanabe, Paula
N1 - Funding Information:
The SCD Implementation Consortium has been supported by US Federal Government co-operative agreements HL133948, HL133964, HL133990, HL133996, HL133994, HL133997, HL134004, HL134007, and HL134042 from the National Heart Lung and Blood Institute and the National Institute on Minority Health and Health Disparities (Bethesda, MD, USA). Jane S. Hankins, Jeffrey Glassberg, Ward Hagar, Allison King, Cathy Melvin, Angela Snyder, Nirmish Shah, and Paula Tanabe were investigators in the parent study and provided access to patients and EHR data housed in the SCDIC. Ebony N. Burns and Laura Van Althius participated in data collection for the parent study. The SCDIC provided allowed access to the data for the current study. Stephanie O. Ibemere, Charity I. Oyedeji, Laura Van Althius, Ebony N. Burns, Liliana Preiss, and Paula Tanabe developed the concept, designed the present study, and drafted the manuscript. Liliana Preiss and John Myers provided statistical analysis support. Liliana Preiss performed the statistical analysis with input from all authors. All authors contributed to data interpretation. All authors provided critical revisions to and approval of the submitted and final versions this manuscript.
Funding Information:
Stephanie O. Ibemere is part of an advisory board for bluebird bio. Laura E. Van Althuis is part of advisory boards and has received speaker honoraria from Baxter Health. Jane S. Hankins is a consultant for GBT, CVS Health, Forma Therapeutics, and bluebird bio. Jeffrey Glassberg is part of advisory boards with Novartis and CSL Behring. Allison King has previously consulted for and currently receives research funding from GBT. Nirmish Shah is a consultant for GBT, Novartis, Forma, Agios, Emmaus Pharmaceuticals, has received speaker honoraria from GBT, Novartis, Emmaus Pharmaceuticals, and Alexion, and research funding from GBT.
Funding Information:
The SCD Implementation Consortium has been supported by US Federal Government co‐operative agreements HL133948, HL133964, HL133990, HL133996, HL133994, HL133997, HL134004, HL134007, and HL134042 from the National Heart Lung and Blood Institute and the National Institute on Minority Health and Health Disparities (Bethesda, MD, USA). Jane S. Hankins, Jeffrey Glassberg, Ward Hagar, Allison King, Cathy Melvin, Angela Snyder, Nirmish Shah, and Paula Tanabe were investigators in the parent study and provided access to patients and EHR data housed in the SCDIC. Ebony N. Burns and Laura Van Althius participated in data collection for the parent study. The SCDIC provided allowed access to the data for the current study. Stephanie O. Ibemere, Charity I. Oyedeji, Laura Van Althius, Ebony N. Burns, Liliana Preiss, and Paula Tanabe developed the concept, designed the present study, and drafted the manuscript. Liliana Preiss and John Myers provided statistical analysis support. Liliana Preiss performed the statistical analysis with input from all authors. All authors contributed to data interpretation. All authors provided critical revisions to and approval of the submitted and final versions this manuscript.
Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2023/3
Y1 - 2023/3
N2 - Individuals with sickle cell disease (SCD) have historically been considered underweight. Despite increasing body mass index (BMI) in the general population, the prevalence of overweight and obese status remains unclear in the adult SCD population. Our primary aim was to determine the prevalence of overweight and obese status and to identify associations between BMI, demographic, and clinical characteristics. We conducted an analysis of abstracted electronic health record data and patient-reported outcomes from the Sickle Cell Disease Implementation Consortium registry; individuals aged 20–45 years were included. The median (interquartile range) BMI for the 1664 adults in this analysis was 23.9 (21.1–28) kg/m2. In this cohort, 42.9% had a BMI of >25 kg/m2 (Centers for Disease Control and Prevention definition of overweight/obese). In multivariable analysis, higher odds of being overweight or obese were associated with female gender, older age, college education, private insurance, and hypertension diagnosis. Higher odds of a BMI of >25 kg/m2 were observed in individuals with HbSC or HbSβ+ thalassaemia regardless of hydroxycarbamide (hydroxyurea) exposure (odds ratio [OR] 3.4, p < 0.0001) and HbSS or HbSβ0 thalassaemia exposed to hydroxycarbamide (OR 1.6, p = 0.0003) compared to those with HbSS or HbSβ0 thalassaemia with no hydroxycarbamide exposure. These data highlight the importance of early identification, prevention, and intervention for increasing BMI to reduce obesity-related complications that may impact SCD-related complications.
AB - Individuals with sickle cell disease (SCD) have historically been considered underweight. Despite increasing body mass index (BMI) in the general population, the prevalence of overweight and obese status remains unclear in the adult SCD population. Our primary aim was to determine the prevalence of overweight and obese status and to identify associations between BMI, demographic, and clinical characteristics. We conducted an analysis of abstracted electronic health record data and patient-reported outcomes from the Sickle Cell Disease Implementation Consortium registry; individuals aged 20–45 years were included. The median (interquartile range) BMI for the 1664 adults in this analysis was 23.9 (21.1–28) kg/m2. In this cohort, 42.9% had a BMI of >25 kg/m2 (Centers for Disease Control and Prevention definition of overweight/obese). In multivariable analysis, higher odds of being overweight or obese were associated with female gender, older age, college education, private insurance, and hypertension diagnosis. Higher odds of a BMI of >25 kg/m2 were observed in individuals with HbSC or HbSβ+ thalassaemia regardless of hydroxycarbamide (hydroxyurea) exposure (odds ratio [OR] 3.4, p < 0.0001) and HbSS or HbSβ0 thalassaemia exposed to hydroxycarbamide (OR 1.6, p = 0.0003) compared to those with HbSS or HbSβ0 thalassaemia with no hydroxycarbamide exposure. These data highlight the importance of early identification, prevention, and intervention for increasing BMI to reduce obesity-related complications that may impact SCD-related complications.
KW - body mass index
KW - high BMI
KW - obesity
KW - overweight
KW - sickle cell disease
UR - http://www.scopus.com/inward/record.url?scp=85142233570&partnerID=8YFLogxK
U2 - 10.1111/bjh.18548
DO - 10.1111/bjh.18548
M3 - Article
C2 - 36382420
AN - SCOPUS:85142233570
SN - 0007-1048
VL - 200
SP - 633
EP - 642
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -